Lundbeck

Activities: Pharmaceutical

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Media

Domain Therapeutics receives $125m to assign its intellectual property

Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by a French biotech
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Moving to continuous processes

As both the regulators and equipment manufacturers push the concept of continuous manufacturing, the mindset is filtering down from research and API production to finished products. But are all the requirements in place to make it successful? Susan Birks reports
Finance

Lundbeck embarks on another restructuring to drive profit and ensure growth

Will cut around 1,000 jobs in Europe
Media

Alzheimer’s treatment market value to exceed US$13bn by 2023

Rising prevalence, advances in diagnostic capability and greater awareness will drive growth

Kåre Schultz appointed as President and CEO of Lundbeck

He joins the company on 20 May 2015
Regulatory

Ulf Wiinberg resigns as CEO of Lundbeck

Following a breach in the company's code of conduct
Finance

Lundbeck to buy Chelsea Therapeutics for US$658m

Danish company gains rights to FDA-approved Northera for the treatment of neurological disorders
Subscribe now